Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khaled Sanber

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
British Journal of Haematology|May 26, 2021
Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cellsKhaled Sanber, Bipin Savani, Tania Jain
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 21, 2023
Neoadjuvant Immunotherapy for Non-Small Cell Lung CancerKhaled Sanber, Samuel Rosner, Patrick M Forde, et al.
Journal of Graduate Medical Education|November 5, 2020
I-PASS Illness Severity Identifies Patients at Risk for Overnight Clinical DeteriorationChirayu Shah, Khaled Sanber, Rachael Jacobson, et al.
Molecular Therapy. Methods & Clinical Development|September 6, 2018
Lentivector Producer Cell Lines with Stably Expressed Vesiculovirus EnvelopesMaha Tijani, Altar M Munis, Christopher Perry, et al.
Journal of Advanced Research|December 15, 2020
Targeting hydrogen sulphide signaling in breast cancerRana Ahmed Youness, Ahmed Zakaria Gad, Khaled Sanber, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Haematologica|October 4, 2024
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agentsSabine Kayser, Khaled Sanber, Giovanni Marconi, et al.
Nature Communications|July 17, 2020
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcomaMeenakshi Hegde, Sujith K Joseph, Farzana Pashankar, et al.
Leukemia|March 25, 2020
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expressionKristen Fousek, Junji Watanabe, Sujith K Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
British Journal of Haematology|May 26, 2021
Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cellsKhaled Sanber, Bipin Savani, Tania Jain
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 21, 2023
Neoadjuvant Immunotherapy for Non-Small Cell Lung CancerKhaled Sanber, Samuel Rosner, Patrick M Forde, et al.
Journal of Graduate Medical Education|November 5, 2020
I-PASS Illness Severity Identifies Patients at Risk for Overnight Clinical DeteriorationChirayu Shah, Khaled Sanber, Rachael Jacobson, et al.
Molecular Therapy. Methods & Clinical Development|September 6, 2018
Lentivector Producer Cell Lines with Stably Expressed Vesiculovirus EnvelopesMaha Tijani, Altar M Munis, Christopher Perry, et al.
Journal of Advanced Research|December 15, 2020
Targeting hydrogen sulphide signaling in breast cancerRana Ahmed Youness, Ahmed Zakaria Gad, Khaled Sanber, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Haematologica|October 4, 2024
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agentsSabine Kayser, Khaled Sanber, Giovanni Marconi, et al.
Nature Communications|July 17, 2020
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcomaMeenakshi Hegde, Sujith K Joseph, Farzana Pashankar, et al.
Leukemia|March 25, 2020
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expressionKristen Fousek, Junji Watanabe, Sujith K Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.
Pageof 2